Search Results - "Wolinsky JS"

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial.

Authors: Wolinsky JS Narayana PA O'connor P et al.

Source: Annals of Neurology. Jan2007, Vol. 61 Issue 1, p14-24. 11p.

MRI aspects of secondary progressive multiple sclerosis.

Authors: Wolinsky, JS¹

Source: Multiple Sclerosis (13524585). Sep2002 Supplement, Vol. 8 Issue 1S, p85-87. 3p.

Multiple sclerosis: clinical presentation, diagnosis and treatment.

Authors: Brod SA Lindsey JW Wolinsky JS

Source: American Family Physician. 9/15/1996, Vol. 54 Issue 4, p1301-1311. 9p.

Prognosis of the individual course of disease - steps in developing a decision support tool for Multiple Sclerosis.

Authors: Daumer, M Neuhaus, A Lederer, C et al.

Source: BMC Medical Informatics & Decision Making. 2007, Vol. 7 Issue 1, p11-6. 6p. 3 Color Photographs, 1 Chart.

Composite end points to assess delay of disability progression by MS treatments.

Authors: Zhang, J Waubant, E Cutter, G et al.

Source: Multiple Sclerosis Journal. Oct2014, Vol. 20 Issue 11, p1494-1501. 8p.

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Authors: Johnson, KP Brooks, BR Ford, CC et al.

Source: Multiple Sclerosis (13524585). Dec2003, Vol. 9 Issue 6, p585-591. 7p.

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Authors: Giovannoni G Airas L Bove R et al.

Corporate Authors: Giovannoni G Airas L Bove R et al.

Source: Lancet (London, England) [Lancet] 2026 May 30; Vol. 407 (10544), pp. 2195-2207.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Authors: Arnold DL Kolind S Assemlal HE et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Jun; Vol. 31 (7), pp. 821-832. Date of Electronic Publication: 2025 Apr 16.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.

Authors: Manouchehrinia A Fitzgerald KC Salter A et al.

Source: Annals of neurology [Ann Neurol] 2025 Nov; Vol. 98 (5), pp. 1057-1069. Date of Electronic Publication: 2025 Aug 07.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE

Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.

Authors: Montalban X Piasecka-Stryczynska K Kuhle J et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Apr; Vol. 30 (4-5), pp. 558-570. Date of Electronic Publication: 2024 Mar 04.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.

Authors: Koch MW Moral E Brieva L et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2023 Dec; Vol. 29 (14), pp. 1776-1785. Date of Electronic Publication: 2023 Oct 13.

Publication Type: Journal Article

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.

Authors: Bayoumi A Thomas JA Alonzo BR et al.

Source: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2025 Mar; Vol. 12 (3), pp. 615-630. Date of Electronic Publication: 2025 Feb 17.

Publication Type: Journal Article

Journal Info: Publisher: Wiley Periodicals, Inc on behalf of American Neurological Association Country of Publication: United States NLM ID: 101623278 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2328-9503 (Electronic) Linking ISSN: 23289503 NLM ISO Abbreviation: Ann Clin Transl Neurol Subsets: MEDLINE

The impact of relapse definition and measures of durability on MS clinical trial outcomes.

Authors: Satyanarayan S Cutter G Krieger S et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2023 Apr; Vol. 29 (4-5), pp. 568-575.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

Authors: Montalban X Vermersch P Arnold DL et al.

Corporate Authors: Montalban X Vermersch P Arnold DL et al.

Source: The Lancet. Neurology [Lancet Neurol] 2024 Nov; Vol. 23 (11), pp. 1119-1132. Date of Electronic Publication: 2024 Sep 19.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.

Authors: Ford CC Cohen JA Goodman AD et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Oct; Vol. 28 (11), pp. 1729-1743. Date of Electronic Publication: 2022 Jun 29.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.

Authors: Arnold DL Sprenger T Bar-Or A et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Oct; Vol. 28 (12), pp. 1927-1936. Date of Electronic Publication: 2022 Jun 07.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Characterizing the time course of cerebrovascular reactivity in multiple sclerosis.

Authors: Lincoln JA Hasan KM Gabr RE et al.

Source: Journal of neuroimaging : official journal of the American Society of Neuroimaging [J Neuroimaging] 2022 May; Vol. 32 (3), pp. 430-435. Date of Electronic Publication: 2022 Feb 14.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 9102705 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-6569 (Electronic) Linking ISSN: 10512284 NLM ISO Abbreviation: J Neuroimaging Subsets: MEDLINE

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.

Authors: Weinstock-Guttman B Bermel R Cutter G et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Apr; Vol. 28 (5), pp. 790-800. Date of Electronic Publication: 2021 Aug 12.

Publication Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.

Authors: Butzkueven H Spelman T Horakova D et al.

Corporate Authors: Butzkueven H Spelman T Horakova D et al.

Source: European journal of neurology [Eur J Neurol] 2022 Apr; Vol. 29 (4), pp. 1082-1090. Date of Electronic Publication: 2021 May 06.

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Authors: Giovannoni G Kappos L de Seze J et al.

Source: European journal of neurology [Eur J Neurol] 2022 Apr; Vol. 29 (4), pp. 1238-1242. Date of Electronic Publication: 2021 May 05.

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE